Join the AACT Inc. Team

• Location(s)
• Job Openings

AACT is a development-stage biopharmaceutical company developing innovative products for treating cancer, zoonotic virus infections, and radiation protection. The Company’s products are small molecule, patent-protected drugs that address unmet markets and the three major problems associated with cancer, viral infections, and radiation protection. We have two compounds currently undergoing IND-enabling studies and are expected to enter Phase-1 clinical trials in the next 6-12 months.

Following the emergence of COVID-19, the company has screened their compound library for compounds that inhibit SARS-CoV-2 replication and has identified several leads that potently inhibit SARS-CoV-2 replication. The company is actively working to advance these compounds against kinase targets that have been strongly implicated in the infection, life cycle, and transmission of infectious viruses, including severe acute respiratory syndrome-related coronaviruses such as SARS-CoV-2.

Protection from exposure to ionizing radiation (IR) has become an important issue due to ever-increasing threats associated with the proliferation of nuclear materials, terrorism and occupational risks associated with medical and space exploration. Due to the limited availability of radioprotective agents, we performed a screen of our small molecule chemical library of kinase inhibitors/agonists for compounds that protect cells from the damaging effects of IR using a high throughput cell-based assay. From this screen, we have identified several compounds that effectively show radioprotective activity, and one of them, AA108770, an agonist of WNT pathway was found be an effective radioprotector in 30-day mouse survival assays when administered 24 post IR exposure. Our goal is to develop further this series of compounds for radioprotection.